Tag: COVAXIN PEER REVIEW
COVAXIN is Safe, Highly Immunogenic in 2-18 Years Old – The Lancet Review
Bharat Biotech today announced COVAXIN Latest Peer Review published in the Lancet Infectious Disease Journal . The company…
6 Key Findings of COVAXIN The Lancet Peer-Review
COVAXIN The Lancet Peer-Review is out now which re-affirms its efficacy and safety. Bharat Biotech, a global leader…